Resistance to Targeted Therapies Against Adult Brain Cancers
Amanda . Ed(S): Tivnan
€ 194.80
FREE Delivery in Ireland
Description for Resistance to Targeted Therapies Against Adult Brain Cancers
Hardback. Editor(s): Tivnan, Amanda. Series: Resistance to Targeted Anti-Cancer Therapeutics. Num Pages: 260 pages, 3 black & white illustrations, 16 colour illustrations, 45 colour tables, biography. BIC Classification: MJCL; MJN; MJX; PSAN. Category: (P) Professional & Vocational. Dimension: 235 x 155 x 18. Weight in Grams: 578.
This volume will bring together a review of research being carried out by international experts in this field, detailing treatment and research approaches in several forms of malignant brain tumors. These include glioblastoma (GBM), a highly aggressive and fatal form of astrocytoma which accounts for 80% of newly diagnosed brain tumor patients per year, and meningioma, of which 10% are malignant and extremely resistant to targeted therapies. The volume will also include a discussion of methods to overcome blood-brain barrier exclusion for more efficient targeted drug delivery in all forms ... Read more
Show LessProduct Details
Format
Hardback
Publication date
2016
Publisher
Springer International Publishing AG Switzerland
Number of pages
260
Condition
New
Series
Resistance to Targeted Anti-Cancer Therapeutics
Number of Pages
260
Place of Publication
Cham, Switzerland
ISBN
9783319465043
SKU
V9783319465043
Shipping Time
Usually ships in 15 to 20 working days
Ref
99-15
About Amanda . Ed(S): Tivnan
Amanda Tivnan, PhD, is Senior Postdoctoral Research Fellow, Department of Physiology and Medical Physics, The Royal College of Surgeons, Dublin, Ireland.
Reviews for Resistance to Targeted Therapies Against Adult Brain Cancers
“This is a complete monograph on the molecular and cell biology of 'brain tumors' resistant mechanisms. The book discusses chemotherapy and radiotherapy of brain malignancies including gliomas, ependynomas, and meningiomas. … I highly recommend this book as a reference and research tool for neurosurgeons, oncologists, neurologists, residents, and students.” (Joseph Grenier, Amazon.de, May, 2018)